Company: OSRH
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-045947
Chunk: 310

Company: OSR Holdings, Inc.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 8
Chunk 310
---
 combination 
     8,751,233  
     - 
  
    Weighted average number of ordinary shares outstanding 
     10,906,233  
     5,622,954 

The
group’s diluted loss per share is the same as basic loss per share because there is no dilution effect.

(23)Business combinations

The
Parent acquired Darnatein (a novel drug development company) (referred as the “Acquiree” herein) as it executes on its business
plan to further expand its business by discovering and investing in innovative healthcare companies with cutting-edge technology and
creating operating synergies between subsidiaries. As the Parent and the Acquiree former owners exchanged only equity interests in business
combination transactions and the acquisition-date fair value of the Parent’s equity interests could not reliably be measured, the
Parent determined the amount of goodwill by using the acquisition-date fair value of the Acquiree equity interests instead of the acquisition-date
fair value of the shares transferred.

Vaximm
(2022 acquisition) and Darnatein can be reasonably categorized as “(bio)platform companies” which differ from the companies
only with drug development pipelines. Bioplatforms can be defined as biotechnologies that, once created and harnessed, allow for the
intentional and repeatable generation of multiple medicines or agricultural and sustainability products. Both Vaximm and Darnatein are
biotech companies whose drug R&D pipelines are based on their own in-house platform technologies that are protected by either patents
or trade secrets. According to the “hub-and-spoke” business model of OSR Holdings, the Parent has assumed the position to
either own or control the technology platforms of Vaximm and Darnatein through the Business Combinations, which means that the Parent
will be able to launch new services to external clients or create additional drug candidates by a new start-up or Joint Venture with
business partners based on their direct ownership or control over the platform technologies acquired from the Business Combinations.
Such quality would support the goodwill recognition.

Details
of business combinations that occurred for the three months ended March 31, 2025 and 2024 are as follows:

        For the year ended December 31, 2023  Acquiree  Main business  Acquisition date  Ownership
(%)   Total
consideration   Darnatein  New drug development, etc.  March 31, 2023